Alcon AG
SIX:ALC
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
63.02
84.68
|
Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ALC stock under the Base Case scenario is 73.08 CHF. Compared to the current market price of 76.68 CHF, Alcon AG is Overvalued by 5%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Alcon AG
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ALC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Alcon AG, a leader in the global eye care industry, is dedicated to enhancing the quality of life for patients through innovative solutions and cutting-edge technologies. Formed in 1945, the company specializes in developing, manufacturing, and marketing surgical and vision care products that cater to a wide range of eye-related conditions. With a robust portfolio that includes advanced cataract surgery instruments, contact lenses, and dry eye treatments, Alcon has positioned itself as a formidable player in both the surgical and non-surgical segments of the market. The company's commitment to research and development ensures a steady stream of innovations, attracting a loyal customer base a...
Alcon AG, a leader in the global eye care industry, is dedicated to enhancing the quality of life for patients through innovative solutions and cutting-edge technologies. Formed in 1945, the company specializes in developing, manufacturing, and marketing surgical and vision care products that cater to a wide range of eye-related conditions. With a robust portfolio that includes advanced cataract surgery instruments, contact lenses, and dry eye treatments, Alcon has positioned itself as a formidable player in both the surgical and non-surgical segments of the market. The company's commitment to research and development ensures a steady stream of innovations, attracting a loyal customer base among healthcare professionals and patients alike.
For investors, Alcon AG presents a compelling opportunity driven by its strong market presence and a favorable demographic backdrop, with an aging population increasingly in need of vision care solutions. The company has demonstrated consistent revenue growth and profitability, buoyed by strategic acquisitions and a willingness to invest in future growth areas, such as digital health and myopia management. Additionally, with a robust pipeline of products and a focus on expanding markets, Alcon is well-positioned to capitalize on the growing demand for eye care solutions. As it continues to navigate the evolving landscape of the healthcare sector, Alcon AG stands out as a promising investment for those seeking exposure to the eye care market.
Alcon AG is a global leader in eye care, specializing in surgical and vision care products. The company operates through two core business segments:
-
Surgical: This segment focuses on providing a wide range of surgical products used to treat various eye conditions, particularly those related to cataracts and refractive surgery. Key offerings in this segment include:
- Intraocular Lenses (IOLs): Used in cataract surgery to replace the eye's natural lens.
- Phacoemulsification Systems: Equipment used to perform cataract surgery, including surgical instruments and consumables.
- Refractive Surgery Devices: Products and systems used for laser vision correction procedures such as LASIK.
-
Vision Care: This segment offers a variety of products designed to improve vision and enhance the daily lives of consumers. Key offerings include:
- Contact Lenses: A wide range of soft contact lenses, including daily disposable lenses, extended wear lenses, and specialty lenses for astigmatism and presbyopia.
- Eye Care Solutions: Products such as lubricating eye drops, allergy relief drops, and other therapeutic eye care solutions aimed at treating dry eyes and other eye conditions.
Together, these segments make Alcon a comprehensive provider of innovative eye care solutions, catering to both healthcare providers and consumers.
Alcon AG, a global leader in eye care, benefits from several unique competitive advantages that enhance its position in the market:
-
Strong R&D Capabilities: Alcon invests heavily in research and development, leading to innovative products in surgical and vision care. Their cutting-edge technology and ability to introduce novel solutions keep them ahead of competitors.
-
Comprehensive Product Portfolio: Alcon offers a wide range of products, including surgical instruments, contact lenses, and over-the-counter eye care solutions. This diversified portfolio caters to various segments of the eye care market, giving them a broader customer base.
-
Brand Recognition: With a long history and a strong reputation in eye care, Alcon is well-recognized in the industry. This brand equity helps retain customer loyalty and attract healthcare professionals who prefer trusted brands.
-
Global Distribution Network: Alcon has an extensive global presence, with significant distribution capabilities that allow them to reach customers in diverse markets. This wide reach helps mitigate regional risks and capitalize on growth opportunities in emerging markets.
-
Strategic Partnerships and Acquisitions: Alcon has consistently engaged in strategic partnerships and acquisitions that enhance its product offerings and market access. This strategy allows them to incorporate new technologies and expertise quickly.
-
Regulatory Expertise: Operating in a heavily regulated industry, Alcon has established strong capabilities in navigating complex regulatory environments. This expertise enables faster product approvals and market entry compared to rivals.
-
Focus on Patient Outcomes: Alcon’s focus on improving patient outcomes through its products not only builds credibility among healthcare providers but also aligns with the increasing emphasis on evidence-based practices in healthcare.
-
Economies of Scale: As one of the largest eye care companies, Alcon can leverage economies of scale in manufacturing, distribution, and marketing, resulting in lower per-unit costs and enhanced pricing power.
-
Strong Financial Position: Alcon's solid financial health provides the resources necessary to sustain investments in R&D, marketing, and strategic initiatives, allowing for sustained innovation and market adaptation.
-
Commitment to Sustainability: Alcon's initiatives in sustainability resonate well with modern consumers and healthcare institutions that prioritize environmental stewardship, setting them apart as a socially responsible choice.
These competitive advantages enable Alcon AG to not only maintain its market leadership but also adapt and thrive in a rapidly evolving eye care sector.
Alcon AG, as a prominent player in the global eye care industry, faces several risks and challenges that could impact its performance in the near future. Here are some of the key factors to consider:
-
Regulatory Compliance: As a medical device and pharmaceutical company, Alcon must adhere to stringent regulations set forth by agencies like the FDA in the U.S. and the EMA in Europe. Any changes in regulatory requirements or failure to comply can result in delays in product launches, fines, or recalls.
-
Market Competition: The eye care market is highly competitive, with numerous players ranging from established companies to new startups. Alcon must continuously innovate and improve its product offerings to maintain its market share, which requires investment in research and development.
-
Product Development Risks: The development of new products involves considerable risks, including clinical trial failures, unforeseen side effects, and longer-than-expected development timelines. These risks can lead to increased costs and negatively impact revenue projections.
-
Supply Chain Disruptions: Global supply chain challenges, exacerbated by events like the COVID-19 pandemic, can affect the availability of raw materials and components necessary for manufacturing. Alcon must ensure robust supply chain management to mitigate these risks.
-
Intellectual Property Challenges: Protecting intellectual property (IP) is crucial in the healthcare sector. Alcon may face patent expirations, challenges from competitors regarding IP validity, or difficulties in enforcing its patents, which could result in loss of competitive advantages.
-
Economic and Political Factors: Economic downturns, changes in healthcare policies, and political instability in key markets can affect consumer spending, reimbursement rates, and overall demand for Alcon's products. This can be particularly impactful in emerging markets.
-
Technological Advancements: Rapid advancements in technology in the eye care sector can create opportunities but also pose threats. Alcon needs to stay ahead of technological trends and adapt to changes, such as telemedicine and digital health solutions.
-
Reimbursement Challenges: Changes in healthcare reimbursement policies, especially in important markets like the U.S. and Europe, may impact Alcon's sales. A shift towards value-based care can change the dynamics of how eye care products and services are reimbursed.
-
Customer Preferences: Shifting consumer preferences and increased awareness about eye health can influence market dynamics. Alcon must ensure its marketing and product development strategies resonate with changing consumer demands.
-
Environmental and Ethical Considerations: Growing scrutiny over environmental practices and corporate social responsibility could impact Alcon’s operations. Failing to address sustainability concerns may harm its brand reputation and consumer loyalty.
By effectively addressing these risks and challenges, Alcon AG can better position itself for future growth and maintain its status as a leader in the eye care market.
Revenue & Expenses Breakdown
Alcon AG
Balance Sheet Decomposition
Alcon AG
Current Assets | 6.3B |
Cash & Short-Term Investments | 1.7B |
Receivables | 1.8B |
Other Current Assets | 2.8B |
Non-Current Assets | 24B |
Long-Term Investments | 705m |
PP&E | 4.8B |
Intangibles | 17.7B |
Other Non-Current Assets | 840m |
Current Liabilities | 2.5B |
Accounts Payable | 849m |
Short-Term Debt | 10m |
Other Current Liabilities | 1.6B |
Non-Current Liabilities | 6.5B |
Long-Term Debt | 4.9B |
Other Non-Current Liabilities | 1.6B |
Earnings Waterfall
Alcon AG
Revenue
|
9.8B
USD
|
Cost of Revenue
|
-4.3B
USD
|
Gross Profit
|
5.4B
USD
|
Operating Expenses
|
-4.1B
USD
|
Operating Income
|
1.3B
USD
|
Other Expenses
|
-154m
USD
|
Net Income
|
1.2B
USD
|
Free Cash Flow Analysis
Alcon AG
USD | |
Free Cash Flow | USD |
In Q3 2024, Alcon generated $2.4 billion in sales, marking a 6% increase, with core earnings per share rising 25% to $0.81. The company reported strong free cash flow of $1.3 billion year-to-date, its highest ever. A notable product launch, the Precision7 contact lens, is set for January 2025. For 2024, Alcon has updated its revenue guidance to $9.8 to $9.9 billion, projecting a constant currency growth rate of 6% to 7%. However, operating margin guidance has been tightened to 20.5% to 21%, reflecting investment in new product launches and inventory pressures.
What is Earnings Call?
ALC Profitability Score
Profitability Due Diligence
Alcon AG's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Alcon AG's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
ALC Solvency Score
Solvency Due Diligence
Alcon AG's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Alcon AG's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALC Price Targets Summary
Alcon AG
According to Wall Street analysts, the average 1-year price target for ALC is 91.57 CHF with a low forecast of 80.72 CHF and a high forecast of 108.15 CHF.
Dividends
Current shareholder yield for ALC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ALC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. The company is headquartered in Fribourg, Fribourg and currently employs 24,389 full-time employees. The company went IPO on 2019-04-09. The firm operates mainly as an eye care device company. Alcon AG reports its activities into two segments: Surgical and Vision Care. The surgical segment provides a line of ophthalmic surgical products that enable surgeons to achieve accurate results. Its surgical portfolio includes technologies and devices for cataract, retinal, refractive surgery, as well as advanced technology intraocular lenses (ATIOLs) to treat cataracts and refractive errors, such as presbyopia and astigmatism. The surgical segment also includes advanced viscoelastics, surgical solutions, surgical packs and other disposable products for cataract and vitreoretinal surgery. The Vision Care segment manufactures contact lenses and lens care products, such as products for dry eye, contact lens care, ocular allergies, as well as ocular vitamins and redness relievers. The firm also offers continuing education for eye care professionals.
Officers
The intrinsic value of one ALC stock under the Base Case scenario is 73.08 CHF.
Compared to the current market price of 76.68 CHF, Alcon AG is Overvalued by 5%.